Compare SCNX & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCNX | CTXR |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 16.8M |
| IPO Year | N/A | 2010 |
| Metric | SCNX | CTXR |
|---|---|---|
| Price | $0.39 | $0.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.50 | ★ $6.00 |
| AVG Volume (30 Days) | 266.6K | ★ 585.2K |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $347.88 | N/A |
| Revenue Next Year | $744.44 | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.63 |
| 52 Week High | $3.17 | $2.38 |
| Indicator | SCNX | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 55.02 |
| Support Level | $0.37 | $0.66 |
| Resistance Level | $0.47 | $0.97 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 17.42 | 58.09 |
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.